Roivant Sciences Ltd.

Roivant Sciences Ltd.

35.03
EUR
+0.12
(+0.33%)
-0.48EPS
23.39BMarket Cap
Feb 15Next Earn

Roivant Sciences Ltd. Documents

Q1 FY2027 · Press release

Roivant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S. _ Roivant Sciences Ltd_ · August 28, 2026 · 7 pages

Read Roivant Sciences Ltd.'s results firsthand

Preview the first 2 pages of this press release
Create a free account to start reading

Full documents are included with Professional

Q1 FY2027 documents